Justin has served as our Chief Financial & Operations Officer since 2023. Justin joined Ardelyx in June 2020 as our Chief Financial Officer. Justin brings more than 25 years of experience in the biopharmaceutical industry, with an extensive array of financial and operational experience.
Prior to Ardelyx, Justin served as the president and chief financial officer of Correvio Pharma, a global specialty pharmaceutical company dedicated to the commercialization of cardiovascular and infectious disease products, where he led the sale of the company to ADVANZ PHARMA in May 2020. Prior to Correvio, Justin was executive vice president, chief financial officer, and treasurer of Karyopharm Pharmaceuticals, where he led core business and finance functions and multiple financings. Before Karyopharm, Justin was executive vice president and chief financial officer at Zalicus Inc. (formerly CombinatoRx, Inc.), which he joined in 2006. At Zalicus, Justin oversaw multiple rounds of equity and debt financings, led the company’s asset monetization strategy and was instrumental in the reverse merger and sale of Zalicus to EPIRUS Biopharmaceuticals Inc. in July 2014. Earlier in his career, Justin held numerous positions of increasing responsibility at EMD Serono Inc., ArQule, Inc., Coley Pharmaceutical Group, and Millipore Corporation.
Justin began his career with Arthur Andersen LLP in 1993. He earned a Bachelor of Arts in economics and accounting from the College of the Holy Cross, a Master of Science in taxation from Northeastern University, and a Master of Business Administration from Suffolk University. He is also a certified public accountant in Massachusetts.
What is Justin A. Renz's net worth?
The estimated net worth of Justin A. Renz is at least $2.42 million as of August 21st, 2025. Mr. Renz owns 409,052 shares of Ardelyx stock worth more than $2,421,588 as of December 4th. This net worth evaluation does not reflect any other assets that Mr. Renz may own. Additionally, Mr. Renz receives a salary of $623,700.00 as Chief Financial & Operations Officer at Ardelyx. Learn More about Justin A. Renz's net worth.
How old is Justin A. Renz?
Mr. Renz is currently 52 years old. There are 6 older executives and no younger executives at Ardelyx. The oldest executive at Ardelyx is Mr. Robert C. Blanks, Chief Regulatory Affairs & Quality Assurance Officer, who is 64 years old. Learn More on Justin A. Renz's age.
What is Justin A. Renz's salary?
As the Chief Financial & Operations Officer of Ardelyx, Inc., Mr. Renz earns $623,700.00 per year. There are 4 executives that earn more than Mr. Renz. The highest earning executive at Ardelyx is Mr. Michael G. Raab, President, CEO & Director, who commands a salary of $1,030,000.00 per year. Learn More on Justin A. Renz's salary.
How do I contact Justin A. Renz?
Has Justin A. Renz been buying or selling shares of Ardelyx?
Justin A. Renz has not been actively trading shares of Ardelyx during the last ninety days. Most recently, Justin A. Renz sold 7,037 shares of the business's stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $5.93, for a transaction totalling $41,729.41. Following the completion of the sale, the chief financial officer now directly owns 409,052 shares of the company's stock, valued at $2,425,678.36. Learn More on Justin A. Renz's trading history.
Who are Ardelyx's active insiders?
Ardelyx's insider roster includes Robert Blanks (Insider), Eric Foster (Chief Commercial Officer), Elizabeth Grammer (Insider), Jeffrey Jacobs (Insider), Mike Kelliher (Insider), David Mott (Director), Michael Raab (CEO), Justin Renz (Chief Financial & Operations Officer), Susan Rodriguez (Insider), David Rosenbaum (Insider), Scott Sandell (Major Shareholder), and Laura Williams (Chief Medical Officer). Learn More on Ardelyx's active insiders.
Are insiders buying or selling shares of Ardelyx?
In the last year, Ardelyx insiders bought shares 7 times. They purchased a total of 1,371,406 shares worth more than $5,780,176.94. In the last year, insiders at the biopharmaceutical company sold shares 26 times. They sold a total of 580,304 shares worth more than $3,050,503.57. The most recent insider tranaction occured on November, 21st when insider Elizabeth A Grammer sold 5,995 shares worth more than $33,212.30. Insiders at Ardelyx own 4.8% of the company.
Learn More about insider trades at Ardelyx. Information on this page was last updated on 11/21/2025.
